Physician profile
Eva Misra
NPI 1578983094
$4,681.67
in general payments reported to CMS, 2019-2025
24 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $497 · 2021: $650 · 2022: $79.82 · 2023: $217 · 2024: $256 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $561.53 | 2024-2025 | Tremfya, Stelara |
| Esperion Therapeutics, INC. | $426.50 | 2021-2022 | |
| Abbvie INC. | $418.15 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.12 | 2025 | Caplyta |
| Pfizer INC. | $314.60 | 2019-2020 | |
| Amgen INC. | $280.46 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $249.96 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $231.68 | 2025 | Symbravo |
| Neurocrine Biosciences, INC. | $176.39 | 2025 | |
| Janssen Pharmaceuticals, INC | $164.97 | 2021-2025 | Spravato |
| Biohaven Pharmaceuticals, INC. | $139.85 | 2020 | |
| Novo Nordisk INC | $134.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $125.13 | 2019 | |
| Optinose US, INC. | $125.00 | 2025 | |
| Lundbeck LLC | $124.98 | 2024 | Vyepti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $122.09 | 2025 | Cobenfy |
| Bayer Healthcare Pharmaceuticals INC. | $121.82 | 2025 | |
| Abbott Laboratories | $121.18 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $108.16 | 2019-2025 | Fasenra |
| Nevro Corp. | $99.55 | 2023 | Senza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.59 | 2019 | |
| Paratek Pharmaceuticals, INC. | $86.58 | 2025 | Nuzyra |
| Amarin Pharma, INC. | $64.89 | 2020 | |
| Portola Pharmaceuticals, LLC | $57.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.